0001193125-18-002218.txt : 20180104 0001193125-18-002218.hdr.sgml : 20180104 20180104080138 ACCESSION NUMBER: 0001193125-18-002218 CONFORMED SUBMISSION TYPE: 424B5 PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20180104 DATE AS OF CHANGE: 20180104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dare Bioscience, Inc. CENTRAL INDEX KEY: 0001401914 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 204139823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B5 SEC ACT: 1933 Act SEC FILE NUMBER: 333-206396 FILM NUMBER: 18508424 BUSINESS ADDRESS: STREET 1: 11119 NORTH TORREY PINES ROAD STREET 2: SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-769-9145 MAIL ADDRESS: STREET 1: 11119 NORTH TORREY PINES ROAD STREET 2: SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: Cerulean Pharma Inc. DATE OF NAME CHANGE: 20090714 FORMER COMPANY: FORMER CONFORMED NAME: Tempo Pharmaceuticals Inc DATE OF NAME CHANGE: 20070604 424B5 1 d448543d424b5.htm 424B5 424B5

Filed Pursuant to Rule 424(b)(5)

Registration No. 333-206396

PROSPECTUS SUPPLEMENT

(To Prospectus dated October 14, 2016)

 

LOGO

 

 

This prospectus supplement supplements our prospectus supplement dated October 18, 2016 relating to our At The Market offering program. Please see the “Explanatory Note” contained herein.

 

 

Investing in our securities involves a high degree of risk. See “Risk Factors” contained in the documents we incorporate by reference in this prospectus supplement to read about factors you should consider before investing in our securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.


EXPLANATORY NOTE

On October 14, 2016, we entered into a common stock purchase agreement (the “Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), relating to our common stock, par value $0.0001 per share (“Common Stock”), having an aggregate offering price of up to $20,000,000 (the “Offering Amount”). In accordance with the terms of the Purchase Agreement, we issued Aspire Capital 70,000 shares of the Company’s Common Stock (as adjusted to reflect the reverse stock split in the ratio of 10 to 1 that was effective on July 20, 2017) as consideration for entering into the Purchase Agreement and Aspire Capital committed to purchase up to the Offering Amount of shares of our Common Stock over a term of 24 months from the execution of the Purchase Agreement (the “Offering Shares”). The purchase price for the Offering Shares would be based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice we were to submit to Aspire Capital from time to time.

We are filing this prospectus supplement to inform investors that we have terminated the At the Market offering program with Aspire Capital, effective from the date hereof.

 

 

 

GRAPHIC 2 g448543g1230100628565.jpg GRAPHIC begin 644 g448543g1230100628565.jpg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end